CN101679953A - 突变的呼肠孤病毒及其制备和使用方法 - Google Patents

突变的呼肠孤病毒及其制备和使用方法 Download PDF

Info

Publication number
CN101679953A
CN101679953A CN200880016669A CN200880016669A CN101679953A CN 101679953 A CN101679953 A CN 101679953A CN 200880016669 A CN200880016669 A CN 200880016669A CN 200880016669 A CN200880016669 A CN 200880016669A CN 101679953 A CN101679953 A CN 101679953A
Authority
CN
China
Prior art keywords
reovirus
sudden change
polypeptide
expression
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880016669A
Other languages
English (en)
Chinese (zh)
Inventor
M·C·科菲
B·G·汤普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolytics Biotech Inc
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of CN101679953A publication Critical patent/CN101679953A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880016669A 2007-05-21 2008-05-21 突变的呼肠孤病毒及其制备和使用方法 Pending CN101679953A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93925507P 2007-05-21 2007-05-21
US60/939,255 2007-05-21
PCT/CA2008/000964 WO2008141448A1 (en) 2007-05-21 2008-05-21 Mutant reoviruses and methods of making and using

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410339446.7A Division CN104195115A (zh) 2007-05-21 2008-05-21 突变的呼肠孤病毒及其制备和使用方法

Publications (1)

Publication Number Publication Date
CN101679953A true CN101679953A (zh) 2010-03-24

Family

ID=40031362

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880016669A Pending CN101679953A (zh) 2007-05-21 2008-05-21 突变的呼肠孤病毒及其制备和使用方法
CN201410339446.7A Pending CN104195115A (zh) 2007-05-21 2008-05-21 突变的呼肠孤病毒及其制备和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410339446.7A Pending CN104195115A (zh) 2007-05-21 2008-05-21 突变的呼肠孤病毒及其制备和使用方法

Country Status (14)

Country Link
US (1) US20080292594A1 (enExample)
EP (1) EP2150613B1 (enExample)
JP (1) JP2010527593A (enExample)
CN (2) CN101679953A (enExample)
AR (1) AR066649A1 (enExample)
AU (1) AU2008253505B2 (enExample)
CA (1) CA2680661C (enExample)
DK (1) DK2150613T3 (enExample)
ES (1) ES2611455T3 (enExample)
IL (1) IL200690A (enExample)
MX (1) MX2009012420A (enExample)
TW (1) TW200909581A (enExample)
WO (1) WO2008141448A1 (enExample)
ZA (1) ZA200907017B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720624D0 (en) * 2007-10-20 2007-11-28 Academisch Ziekenhuis Leiden Viral Modification
AU2008316276A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
US20110086005A1 (en) * 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
CA2819236A1 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
MX373096B (es) 2010-12-02 2020-04-27 Oncolytics Biotech Inc Formulaciones virales líquidas.
ES2796950T3 (es) 2013-11-15 2020-11-30 Oncolytics Biotech Inc Virus oncolíticos y regímenes reforzados para tratamiento de cáncer
WO2017141942A1 (ja) 2016-02-16 2017-08-24 国立大学法人大阪大学 線維化を治療するための医薬組成物
KR20210098202A (ko) * 2020-01-31 2021-08-10 바이로큐어 주식회사 레오바이러스를 유효성분으로 포함하는 대장염의 예방 또는 치료용 조성물
CN116917468A (zh) * 2020-12-22 2023-10-20 百洛克株式会社 新型修饰的呼肠孤病毒及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
DE69937999T2 (de) * 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag Interferon induzierende genetisch veränderte attenuierte viren
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
ES2445704T3 (es) * 2000-11-09 2014-03-04 Oncolytics Biotech Inc. Métodos para el tratamiento de trastornos celulares proliferativos
IL157304A0 (en) * 2001-03-16 2004-02-19 Oncolytics Biotech Inc Method of extracting virus from cell culture
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
WO2007099401A2 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders

Also Published As

Publication number Publication date
AU2008253505B2 (en) 2014-09-04
CA2680661A1 (en) 2008-11-27
WO2008141448A1 (en) 2008-11-27
CA2680661C (en) 2018-05-29
HK1136006A1 (en) 2010-06-18
ES2611455T3 (es) 2017-05-09
EP2150613B1 (en) 2016-10-19
IL200690A0 (en) 2011-08-01
US20080292594A1 (en) 2008-11-27
DK2150613T3 (en) 2017-01-30
JP2010527593A (ja) 2010-08-19
AU2008253505A1 (en) 2008-11-27
ZA200907017B (en) 2010-12-29
IL200690A (en) 2014-02-27
EP2150613A1 (en) 2010-02-10
MX2009012420A (es) 2009-12-09
EP2150613A4 (en) 2011-01-19
TW200909581A (en) 2009-03-01
CN104195115A (zh) 2014-12-10
AR066649A1 (es) 2009-09-02

Similar Documents

Publication Publication Date Title
US11246930B2 (en) Reoviruses having modified sequences
AU2008253505B2 (en) Mutant reoviruses and methods of making and using
TW200951143A (en) Modulating interstitial pressure and oncolytic viral delivery and distribution
AU2009253683B2 (en) Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
HK1136006B (en) Mutant reoviruses and methods of making and using
WO2015017915A1 (en) Methods of treating taxane naïve subjects with primary tumors or with metastatic cancer
HK1132761B (en) Reoviruses having modified sequences

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100324